DOJ Drops Criminal Probe into Abbott's Baby Formula Plant, Removing Major Legal Overhang
ABT is trading near its 52-week low of $81.97 (14% above the low).
Summary
The Department of Justice has dropped its criminal investigation into Abbott Laboratories concerning its baby formula facility. This probe originated from the 2022 discovery of potentially deadly bacteria at Abbott's Sturgis, Michigan plant, which was linked to infant illnesses and deaths and contributed to a national formula shortage. The decision to not pursue criminal charges, despite prosecutors believing they had evidence, removes a significant criminal liability and reputational risk for Abbott. While the criminal case is closed, the DOJ confirmed it resolved concerns through a related civil lawsuit focused on sales through federal nutrition programs, which is expected to result in a "significant recovery for taxpayers" once finalized.
At the time of this announcement, ABT was trading at $93.81 on NYSE in the Life Sciences sector, with a market capitalization of approximately $163.9B. The 52-week trading range was $81.97 to $137.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.